AngioDynamics names Eric Honroth as new CEO, effective Nov. 2

AngioDynamics, Inc. (ANGO) named Eric Honroth as President and CEO, effective Nov. 2, 2026. He replaces Jim Clemmer, who will leave the board but stay as a consultant. The company aims to advance its transformation and Med Tech momentum under new leadership, according to the press release.

AngioDynamics (NASDAQ:ANGO) said MedTech is expected to become a majority of revenue by fiscal 2027, citing Auryon share gains and ongoing AMBITION BTK enrollment. Management expects no Auryon study data in fiscal 2027, discussed possible coronary use, and guided fiscal 2027 gross margin to 54% to 55% and adjusted EBITDA to $13M to $16M.

AngioDynamics (ANGO) held its fiscal 2026 Q4 and full-year earnings call. The company said full-year Med Tech growth was over 18% and reported Q4 revenue up 8% to $86.6 million. Q4 Med Tech revenue was $41.8 million (+16.7%). Auryon revenue was $17.8 million (+14.4%). Mechanical thrombectomy revenue was $11.1 million (-1.1%), with AlphaVac up 38.4% and AngioVac down 15.8%. Catalysts include IDE approvals for AlphaReturn and an AngioVac study.

ANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20077916_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability Delivered its seventh consecutive quarter of double-digit

Needham maintained a Buy rating on Levi Strauss (LEVI) with a $28 price target, suggesting a 43.5% upside. The firm cited strong Q4 growth projections due to reaccelerating DTC sales and effective use of $80M in tariff refunds for marketing and supply chain improvements.

JPMorgan raised its price target for Valero Energy from $339 to $439. The stock has seen a 5-day change of $424.10 USD, a 1st Jan change of +1.16%, and a 1-year change of +160.52%.